News|Articles|August 5, 2024

Pharma Pulse 8/5/24: Pharmacists Enhancing RSV Care, China Wants to Start a National Internet ID System & more

The latest news for pharma industry insiders.

The Site Council Value Calculator: A New Tool for Optimizing Site Payments

Giving sites and sponsors an effective tool for principled negotiations.

Pharmacists Enhancing RSV Care

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides key takeaways and advice to pharmacists on the administration of RSV vaccines.

China Wants to Start a National Internet ID System

The government said the proposal would protect online privacy. Critics said it could further concentrate government control over the internet.

National Poll of Likely 2024 Voters Shows Strong Bipartisan Support for Specific PBM Reform Policies and Candidates Who Support Them

On the heels of the latest Congressional hearing about pharmacy benefit managers (PBMs), a damaging report from the Federal Trade Commission and numerous media stories questioning concerning practices of these health insurance middlemen, a national poll released today demonstrates significant bipartisan support for legislation to set rules to eliminate PBM conflicts of interest and bring down patients’ out-of-pocket prescription drug costs.

webmd on Threads

Millennials and Generation Xers are now more likely to be diagnosed with 17 types of cancer, compared to Baby Boomers, during early adulthood and middle age. wb.md/3Wy39…

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.